Table 1 Anthropometric and metabolic characteristics of successfully genotyped glucose-tolerant Danes from the Inter99 cohort stratified according to ACADS rs2014355 (T/C) and ACADM rs11161510 (C/T) genotype, respectively.

2,576 (1,208/1,368)

1,496 (694/802)

252 (105/147)

2,121(991/1,130)

1,821(825/996)

395(186/209)

45 ± 8

45 ± 8

45 ± 8

45 ± 8

45 ± 8

46 ± 8

25.5 ± 4.1

25.4 ± 3.9

25.8 ± 4.0

0.03 (-0.16;0.23)

0.74

25.5 ± 4.0

25.6 ± 4.2

25.4 ± 3.8

0.03 (-0.16;0.21)

0.79

Plasma glucose (mmol/l)

5.3 ± 0.4

5.3 ± 0.4

5.3 ± 0.4

0.005 (-0.013;0.024)

0.55

5.3 ± 0.4

5.3 ± 0.4

5.3 ± 0.4

0.016 (-0.001;0.033)

0.06

8.2 ± 1.5

8.2 ± 1.5

8.1 ± 1.6

-0.05 (-0.12;0.02)

0.18

8.2 ± 1.5

8.1 ± 1.5

8.3 ± 1.5

-0.02 (-0.08;0.05)

0.60

5.5 ± 1.1

5.5 ± 1.2

5.5 ± 1.1

-0.03 (-0.08;0.03)

0.36

5.5 ± 1.1

5.5 ± 1.1

5.5 ± 1.2

-0.004 (-0.05;0.05)

0.88

183.7 ± 100.3

177.9 ± 102.0

175.5 ± 100.7

-4.90 (-9.82;0.01)

0.05

183.7 ± 99.3

177.5 ± 100.8

183.3 ± 103.7

-2.9 (-7.5;1.6)

0.21

Serum insulin (pmol/l)

31 (22-46)

31 (22-46)

29 (23-41)

-1,9% (-4.3%;0.6%)

0.14

31 (22-46)

31 (22-45)

31 (23-46)

0.3% (-2.0%;2.6%)

0.83

246 (177-356)

239 (175-329)

234 (181-302)

-3.8% (-6.3%;-1.3%)

0.003

239 (175-337)

244 (178-351)

245 (173-348)

0.5% (-1.8%;2.8%)

0.65

137 (88-212)

139 (86-209)

130 (87-189)

-1.1% (-4.5%;2.4%)

0.51

140 (87-212)

136 (88-208)

129 (80-214)

-2.8% (-5.9%;0.3%)

0.08

18,220 (12,600-25,830)

17,260 (12,700-23,980)

16,200 (12,630-22,720)

-3.6% (-6.3%;-0.9%)

0.009

17,740 (12,720-24,780)

17,780 (12,600-25,380)

17,670 (12,490-25,790)

0.1% (-2.3%;2.6%)

0.91

Serum C-peptide (pmol/l)

495 (392-632)

499 (394-642)

484 (399-627)

0.2% (-1.3%;1.8%)

0.78

498 (393-639)

494 (392-632)

496 (405-627)

-0.4% (-1.8%;1.0%)

0.61

1,910 (1,490-2,390)

1,840 (1,470-2,310)

1,820 (1,450-2,268)

-1.8% (-3.4%;-0.1%)

0.03

1,880 (1,480-2,350)

1,870 (1,490-2,398)

1,870 (1,450-2,295)

0.3% (-1.2%;1.8%)

0.71

1,960 (1,500-2,490)

1,980 (1,490-2,490)

1,940 (1,450-2,410)

-0.2% (-2.0%;1.7%)

0.84

1,980 (1,500-2,508)

1,960 (1,490-2,480)

1,960 (1,480-2,490)

-1.3% (-3.0%;0.4%)

0.13

149,800 (117,600-185,000)

147,300 (117,700-181,600)

138,500 (117,400-178,400)

-1.8% (-3.4%;-0.1%)

0.03

148,800 (117,100-184,100)

148,000 (118,500-183,200)

147,900 (116,600-183,800)

-0.1% (.1.7%;1.4%)

0.85

Derived indices

7.5 (5.2-11.0)

7.4 (5.1-11.0)

6.8 (5.3-9.6)

-1.8% (-4.4%;0.7%)

0.16

7.4 (5.1-11.0)

7.5 (5.2-10.9)

7.4 (5.3-11.0)

0.6% (-1.8%;3.0%)

0.63

10.3 ± 3.7

10.4 ± 3.8

10.6 ± 3.5

0.14 (-0.05;0.34)

0.14

10.4 ± 3.7

10.3 ± 3.7

10.3 ± 3.6

-0.01 (-0.19;0.17)

0.93

79.9 (48.9-130.7)

74.7 (49.2-123.4)

77.1 (51.5-121.7)

-0.8% (4.2%;2.5%)

0.63

75.9 (48.2-123.9)

80.0 (51.1-136.8)

75.8 (46.5-126.4)

2.6% (0.5%;5.7%)

0.10

9.3 (5.1-17.7)

9.3 (5.1-18.1)

10.6 (5.7-18.7)

0.7% (-3.1%;4.5%)

0.73

9.4 (5.3-18.2)

9.4 (5.0-17.6)

9.2 (4.9-16.7)

-3.5% (7.9%;0.8%)

0.11

25.2 (17.8-35.4)

26.1 (18.2-35.9)

27.9 (20.1-36.0)

2.9% (0.5%;5.2%)

0.02

26.0 (18.0-35.4)

25.3 (17.9-35.7)

25.6 (18.1-35.7)

-0.2% (2.3%;2.0%)

0.87

1,690 (1,344-2,149)

1,655 (1,356-2,056)

1,625 (1,317-2,067)

-2.2% (-4.2%;0.2%)

0.03

1,668 (1,356-2,099)

1,684 (1,351-2,140)

1,712 (1,303-2,048)

0.2% (-1.6%;2.0%)

0.83

27.8 (20.2-38.4)

27.0 (20.5-36.1)

24.9 (19.8-35.1)

-0.03%(-0.05%;-0.01%)

0.01

27.1 (20.3-37.0)

27.6 (20.4-38.2)

27.7 (19.8-38.3)

0.002%(-0.019%; 0.023%)

0.87

Genotype distribution and allele frequency among patients with T2D and glucose-tolerant control individuals

n (men/women)

WT (%)

HE (%)

HO (%)

MAF (95% CI)

OR (95% CI)

P _add

NGT

4,824 (2,239/2,585)

2,872 (59.5)

1,673 (34.7)

279 (5.8)

23.1 (22.3-24.0)

1.07 (0.96-1.18)

0.21

T2D

3,489 (2,063/1,426)

2,030 (58.2)

1,243 (35.6)

216 (6.2)

24.0 (23.0-25.0)

NGT

4,841 (2,237/2,604)

2,353 (48.6)

2,053 (42.4)

435 (9.0)

30.2 (29.3-31.1)

1.01 (0.92-1.11)

0.80

T2D

3,503 (2,083/1,420)

1,686 (48.1)

1,486 (42.4)

331 (9.4)

30.7 (29.6-31.8)